ARRY-797 (ARRY-371797)

Target: p38 | Disease State: LMNA-DCM

Introduction / Brief Description

ARRY-797 is an oral, selective p38 mitogen-activated protein kinase inhibitor. ARRY-797 is being studied in a Phase 3 trial in patients with lamin A/C-related dilated cardiomyopathy (LMNA-related DCM), a rare, degenerative cardiovascular disease caused by mutations in the LMNA gene and characterized by poor prognosis.

Clinical Trials

Trial Data
Trial Title
Program: ARRY-797
Phase: 3
Status: Recruiting
Disease: LMNA-related dilated cardiomyopathy
Sponsor: Array
Trial Information: NCT03439514
Trial Title: A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

To learn more about ARRY-797 clinical trials, click here.

Publications and Presentations

ARRY-797

08/31/2016

European Society of Cardiology Congress 2016

Phase 2 Study of A797, an Oral, Selective p38 Mitogen-Activated Protein Kinase Inhibitor, in Patients With Lamin A/C–Related Dilated Cardiomyopathy

C. A. MacRae, et al.

ARRY-797

07/05/2012

Human Molecular Genetics

Abnormal p38 mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation

A. Muchir, et al.

ARRY-797

11/15/2011

Circulation

Inhibition of Site Specific Phosphorylation of Retinoblastoma Protein by a p38 Inhibitor Decreases Apoptosis, Improves Survival and Prevents Cardiomyopathy Caused by a Mutation in LMNA gene

A. Saqib, et al.


To view all publications, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.